Cargando…
Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies
INTRODUCTION: Naldemedine is a peripherally-acting µ-opioid-receptor antagonist, approved in Japan for opioid-induced constipation (OIC). In two open-label, single-arm, Phase III studies, we evaluated the safety and efficacy of naldemedine in Japanese patients with OIC receiving regular-use opioids...
Autores principales: | Saito, Yoji, Yokota, Takaaki, Arai, Masatsugu, Tada, Yukio, Sumitani, Masahiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307491/ https://www.ncbi.nlm.nih.gov/pubmed/30613161 http://dx.doi.org/10.2147/JPR.S175900 |
Ejemplares similares
-
Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain
por: BouSaba, Joelle, et al.
Publicado: (2022) -
Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer
por: Katakami, N, et al.
Publicado: (2018) -
Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies
por: Osaka, Iwao, et al.
Publicado: (2019) -
Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy
por: Stern, Emily K, et al.
Publicado: (2018) -
Onset of action of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: results from 2 randomized, placebo-controlled, phase 3 trials
por: Wild, James, et al.
Publicado: (2019)